Programme Book

EMUC16
Consolidating multidisciplinary strategies
24-27 November 2016, Milan, Italy

ESUI16
5th Meeting of the EAU Section of Urological Imaging

8th European Multidisciplinary Meeting on Urological Cancers

In conjunction with the:
• European School of Urology (ESU)
• 5th Meeting of the EAU Section of Urological Imaging (ESUI)
• EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics (ESUP)
• EAU Young Academic Urologists Meeting (YAU)

www.emuc16.org
Selected webcasts will be available shortly after the sessions

www.emuc16.org
## Table of contents

<table>
<thead>
<tr>
<th>Welcome</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organising Committees</td>
<td>6</td>
</tr>
<tr>
<td><strong>General Information</strong></td>
<td>7</td>
</tr>
<tr>
<td>Floorplan</td>
<td>10</td>
</tr>
<tr>
<td>CME Accreditation</td>
<td>12</td>
</tr>
<tr>
<td>Faculty</td>
<td>14</td>
</tr>
<tr>
<td><strong>Scientific Programme</strong></td>
<td>16</td>
</tr>
<tr>
<td><strong>Thursday, 24 November</strong></td>
<td>16</td>
</tr>
<tr>
<td>ESUI</td>
<td>16</td>
</tr>
<tr>
<td>ESU Courses</td>
<td>20</td>
</tr>
<tr>
<td>ESUP</td>
<td>23</td>
</tr>
<tr>
<td><strong>Friday, 25 November</strong></td>
<td>25</td>
</tr>
<tr>
<td>ESU/ERUS HOT Robotic surgery - Intro course</td>
<td>25</td>
</tr>
<tr>
<td>ESU/ESUT/ESUI HOT MRI fusion biopsy</td>
<td>25</td>
</tr>
<tr>
<td>ESU/ESUT HOT Laparoscopy - Virtual procedural training</td>
<td>26</td>
</tr>
<tr>
<td>EMUC</td>
<td>27</td>
</tr>
<tr>
<td><strong>Saturday, 26 November</strong></td>
<td>30</td>
</tr>
<tr>
<td>ESU/ERUS HOT Robotic surgery - Advanced virtual robotic procedural training</td>
<td>30</td>
</tr>
<tr>
<td>ESU/ESUT/ESUI HOT MRI fusion biopsy</td>
<td>30</td>
</tr>
<tr>
<td>ESU/ESUT HOT Laparoscopy - Virtual procedural training</td>
<td>31</td>
</tr>
<tr>
<td>FALCON Workshop</td>
<td>32</td>
</tr>
<tr>
<td>Uropathology Training Workshop for clinicians</td>
<td>33</td>
</tr>
<tr>
<td>EMUC</td>
<td>34</td>
</tr>
<tr>
<td><strong>Sunday, 27 November</strong></td>
<td>37</td>
</tr>
<tr>
<td>EAU YAU</td>
<td>37</td>
</tr>
<tr>
<td>EMUC</td>
<td>38</td>
</tr>
<tr>
<td><strong>About the Organisers</strong></td>
<td>40</td>
</tr>
<tr>
<td>About ESMO</td>
<td>40</td>
</tr>
<tr>
<td>About ESTRO</td>
<td>42</td>
</tr>
<tr>
<td>About EAU</td>
<td>46</td>
</tr>
<tr>
<td>About ESU</td>
<td>48</td>
</tr>
<tr>
<td>About ESUI</td>
<td>49</td>
</tr>
<tr>
<td>About YAU</td>
<td>50</td>
</tr>
<tr>
<td><strong>Industry</strong></td>
<td>51</td>
</tr>
<tr>
<td>Industry Sessions</td>
<td>51</td>
</tr>
<tr>
<td>Exhibition: Company Profiles</td>
<td>54</td>
</tr>
<tr>
<td>Sponsor Acknowledgements</td>
<td>59</td>
</tr>
</tbody>
</table>
Download the EMUC16 app

Instant access to all meeting info for ESUI16 and EMUC16

Do not miss it and join the voting sessions!

Download the ESUI16/EMUC16 app and use your mobile device to vote during EMUC!
Welcome

Dear Colleagues,

We welcome you to the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC), an annual meeting that enables specialists to share best practices, skills and insights on current and emerging treatment strategies.

The last seven editions have shown that amid the changing evolution in therapies across the various disciplines of surgery, oncology and onco-radiology, the need to critically discuss issues and align our practices becomes all the more essential in our goal to deliver optimal care to patients with urological malignancies.

With the collaboration of the European Society for Medical Oncology (ESMO), European Society for Radiotherapy & Oncology (ESTRO) and the European Association of Urology (EAU), the EMUC serves as an indispensable platform where we do not only integrate the latest research outcomes with clinical practices, but also identify areas for further improvement from diagnosis, treatment to follow-up care.

The Scientific Programme is preceded by two simultaneous meetings: the EMUC Symposium on Genitourinary Pathology (ESUP) and the 5th annual meeting of the EAU Section of Urological Imaging (ESUI). Expert discussions in these meetings will focus on new and current diagnostic issues in genitourinary cancers, and the challenges and prospects in imaging.

The European School of Urology (ESU) also offers two courses on managing advanced metastatic urological cancers and another on the multidisciplinary approach in managing genito-urinary cancers. ESU Hands-on Training courses on robotic surgery and MRI fusion biopsy and Laparascopy will be presented on Days 1 and 2. Participants can join the third Falcon Workshop and, for the first time, the Uropathology Training Workshop for Clinicians will be offered.

Milan, one of Italy’s most cosmopolitan centres, provides a dynamic venue and backdrop to this year’s meeting which we hope will not only lead to collaborative links but also ensure that we come up with innovative approaches in our daily clinical work.

Welcome to Milan for the 8th EMUC!

Dr. Thomas Powles  Prof. Peter Hoskin  Prof. Hein Van Poppel
London (GB), ESMO  Northwood (GB), ESTRO  Leuven (BE), EAU
Organising Committees

EMUC 2016 Organising Steering Committee
ESMO       Dr. Thomas Powles, London (GB)
ESTRO      Prof. Peter Hoskin, Northwood (GB)
EAU        Prof. Hein Van Poppel, Leuven (BE)

EMUC 2016 Scientific Committee
ESMO       Dr. Jan Oldenburg, Oslo (NO)
ESMO       Prof. Manuela Schmidinger, Vienna (AT)
ESTRO      Prof. Barbara Jereczek-Fossa, Milan (IT)
ESTRO      Dr. Bradley Pieters, Amsterdam (NL)
EAU        Prof. Alberto Briganti, Milan (IT)
EAU        Prof. George Thalmann, Berne (CH)
EORTC GUCG Prof. Bertrand Tombal, Brussels (BE)
EUOG       Prof. Susanne Osanto, Leiden (NL)
ESUR       Prof. Raymond Oyen, Leuven (BE)
ESUR       Prof. Harriet Thoeny, Berne (CH)
ESUP/ESP   Prof. Rodolfo Montironi, Ancona (IT)
ESUI       Dr. Jochen Walz, Marseille (FR)
YAU        Prof. Mesrur Selçuk Silay, Istanbul (TR)

EMUC Congress Office
Congress Consultants B.V.
PO Box 30016
6803 AA Arnhem
The Netherlands

T +31 (0)26 389 1751
F +31 (0)26 389 1752

emuc2016@congressconsultants.com
www.emuc16.org
General Information

Abstracts and Posters
The ESUI16 abstracts and posters are available online on www.esui16.org and in the ESUI16/EMUC16 app.

The EMUC16 abstracts and posters are available online on www.emuc16.org and in the ESUI16/EMUC16 app.

Address
MiCo – Milano Congressi
Gate 3 (Viale Eginardo / Via Colleoni)
20149, Milan, Italy
T: +39 02 43 42 62 75
F: +39 02 48 01 02 70
www.micmilano.it

App
The ESUI16/EMUC16 app is available in the App and Play store.

Catering
Coffee breaks and lunches will take place in the exhibition area.

Certificate of Attendance

Before obtaining your Certificate of Attendance, you will be requested to enter the number under the barcode on your badge to log in (type the number without the *) as well as complete the evaluation questionnaire. It is therefore important to retain the delegate badge for this purpose.

Cloakroom/luggage
A cloakroom is located close to the registration area and is at the participant’s disposal during meeting hours. Be sure to collect all your personal belongings at the end of the day.

Congress Bag
Each delegate can collect a congress bag in the registration area.

Currency
The currency of Italy is the Euro. The nearest bank to the congress venue is “Barclays Bank”, at 5 minutes walking distance.

Disclosure links to Industry
It is requested that all faculty disclose to the audience any links with the industry related to the topic of their lecture at the beginning of each presentation. A link can be: Being a member of the advisory board or having a consulting agreement with a specific company.

Emergency Information
In case of emergency call the nationwide emergency number 112. Contact the security or the organisation at the congress venue immediately in case of an emergency. Local phone numbers:
Police 113
Fire brigade 115
Ambulance/first aid 118

Electricity
Electricity supply in Milan is 220 Volts and the connection is made by a two-pin plug. Please be aware that delegates from the USA will require a voltage converter. Delegates from the United Kingdom will require a plug adapter.
General Information

Exhibition
An exhibition will be held jointly with the meetings: EMUC, ESUI, ESU and YAU. Only delegates with a “P” on their badge have access to industry-sponsored sessions and exhibition stands related to prescription-only medicines. See page 54 for more information and profiles profiles of the exhibiting companies.

Opening hours:
Thursday, 24 November 10.00 - 17.00 hrs
Friday, 25 November 09.00 - 17.00 hrs
Saturday, 26 November 09.00 - 17.00 hrs

Insurance
The organisers do not accept responsibility for any personal damage. Participants are strongly recommended to arrange their own personal insurance.

Language
All presentations during the meeting will be conducted in English. No translation will be provided.

Lost and Found
Found items should be returned to the registration desk. If you lose something, please report to this desk for assistance.

Mobile phones
During all sessions, please switch your phone to silent and turn off your flash when taking pictures.

Poster Builder Service
Poster presenters who created their posters for EMUC16 and ESUI16 through the “PosterSessionOnline” printing & delivery service, can collect their poster at the faculty help desk, located in the registration area.

Prayer room
Special room dedicated to prayer is located in Suite 7 on Level 2 Mezzanine.

Resource centre
All meeting content will be made available in the Resource centre at rc.emuc16.org

Press
Journalists can obtain free registration to the meeting. All media operators must show their credentials (press card dated 2015/2016 and original assignment letter).

Registration area
The registration area is located on level 2 of the congress centre.

Opening hours:
Wednesday, 23 November 16.00 - 18.30 hrs
Thursday, 24 November 07.15 - 18.00 hrs
Friday, 25 November 07.00 - 19.00 hrs
Saturday, 26 November 08.00 - 19.00 hrs
Sunday, 27 November 08.00 - 13.00 hrs

Registration costs
ESUI: €55.00 ex. VAT (when combined with EMUC registration) €225.00 (normal fee)
For other prices and discounts, please go to the registration desk
ESU Courses: €80.00 (€50.00 EAU, ESMO or ESTRO members)
ESUP: €50.00
Hands-on Training (HOT) courses: €45.00 (€31.00 residents/PhD/medical students, nurses)
EMUC: €615.00 (onsite registration fee)
FALCON Workshop: €55.00
**Uropathology:** Free of charge (NOTE: registration is mandatory).

**Security and Safety**
The safety of all congress attendees is of utmost importance to the EMUC Congress Office. MiCo and the organisers have taken security precautions to ensure the maximum possible safety for all EMUC16 participants. All bags may be subject to inspection. Please take all personal effects with you when leaving a session room.

**Scientific Posters**
The scientific posters are displayed on 24 - 27 November in the poster area. Members of the EMUC Scientific Committee will visit the EMUC poster area to discuss the posters with the presenters according to the following schedule:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Topic</th>
<th>Poster Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday, 25 November</td>
<td>10.45 - 11.15 hrs</td>
<td>Prostate cancer</td>
<td>P001-P021</td>
</tr>
<tr>
<td>Friday, 25 November</td>
<td>13.00 - 14.15 hrs</td>
<td>Prostate cancer</td>
<td>P022-P075</td>
</tr>
<tr>
<td>Friday, 25 November</td>
<td>15.45 - 16.15 hrs</td>
<td>Prostate cancer</td>
<td>P076-P098</td>
</tr>
<tr>
<td>Saturday, 26 November</td>
<td>10.45 - 11.15 hrs</td>
<td>Bladder Cancer</td>
<td>P099-P120</td>
</tr>
<tr>
<td>Saturday, 26 November</td>
<td>13.00 - 14.15 hrs</td>
<td>Bladder Cancer &amp; Renal Cell Carcinoma</td>
<td>P121-P154</td>
</tr>
<tr>
<td>Saturday, 26 November</td>
<td>16.35 - 17.00 hrs</td>
<td>Testicular &amp; Penile</td>
<td>P155-P160</td>
</tr>
</tbody>
</table>

For those who present their poster on Friday you are kindly invited to attend the scientific programme on Saturday when we will announce the best poster at 14:30 hrs, in the main auditorium. For those who present their poster on Saturday you are kindly invited to attend the scientific programme on Sunday. The best poster will be announced at 09.15 hrs in the main auditorium.

The poster area is open during the following times:

- Thursday, 24 November 10.00 - 17.00 hrs
- Friday, 25 November 09.00 - 17.00 hrs
- Saturday, 26 November 09.00 - 17.00 hrs
- Sunday, 27 November 09.15 - 12.30 hrs

**Smoking Policy**
Smoking is prohibited inside the congress venue. Please respect this no-smoking policy for normal and e-cigarettes.

**Social Media**
The use of social media is encouraged to create an open discussion on urology science and experiences at the congress. You are invited to use the hashtag #ESUI16 and #EMUC16 on Twitter and Facebook to discuss the congress, and join the conversation!

**Speaker Service Centre (SSC)**
All presentations should be handed in at the Speaker Service Centre (located in Suite 1, Level 2), at least three hours prior to the start of the session.

Opening hours:

- Wednesday, 23 November 16.00 - 18.00 hrs
- Thursday, 24 November 07.00 - 18.30 hrs
- Friday, 25 November 07.00 - 19.00 hrs
General Information

Saturday, 26 November 08.00 - 19.00 hrs
Sunday, 27 November 08.15 - 12.30 hrs

Transportation
The MiCo – Milano Congressi can be well reached by public transport. The public transport system in Milan is easy to use and a very efficient way to get around the city. The nearest metro station to the entrance (Gate 3) is “Portello”. Follow the purple metro line M5. You can also take a taxi from one of the many taxi stops, or you can call a taxi to come pick you up via 0039 02 4040 or 0039 02 6969. In case you travel by car, follow the signs to “Fieramilanocity”. You can park your car at the parking place “Portello” at the Viale Eginardo across gate 3.
Delegates can collect a complimentary transportation pass in the registration area. The transportation pass is valid during 4 days and can be used for unlimited travel in busses, subways and trams within the city of Milan during the meeting.

Tourist Information
For information about Milan, you can go to the Milan Info Desk, or visit http://www.turismo.milano.it/ to find additional information.

Webcasts
All sessions during ESUI16/EMUC16 in Milan will be broadcasted via www.emuc16.org, under the condition that the speaker has given his or her approval.

WI-FI
Free wireless internet will be available in all areas and session rooms. Please search for the “EMUC2016” network and connect by entering the following password: EMUC2016.
Continuing Medical Education Accreditation EMUC16

The ‘8th European Multidisciplinary Meeting on Urological cancers (EMUC)’ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The ‘8th European Multidisciplinary Meeting on Urological cancers (EMUC)’ is designated for a maximum of (or ‘for up to’) 18 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Continuing Medical Education Accreditation YAU16
The YAU Meeting is granted 1 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

The event has also been accredited with 18 ESMO-MORA category 1 credits.
Continuing Medical Education Accreditation ESUI16

The 5th Meeting of the EAU Section of Urological Imaging (ESUI)' (6 CME points) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The meeting is designated for a maximum of 6 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.
## Faculty list

**EMUC Faculty**  
M. Albersen, Leuven (BE)  
L. Albíges, Villejuif (FR)  
T. Albreht, Ljubljana (SI)  
A. Alcaraz, Barcelona (ES)  
M. Amin, Los Angeles (US)  
C. Bangma, Rotterdam (NL)  
J. Bedke, Tübingen (DE)  
A. Bex, Amsterdam (NL)  
A. Bjartell, Malmö (SE)  
A. Bossi, Villejuif (FR)  
S. Boxler, Berne (CH)  
A. Briganti, Milan (IT)  
M. Brock, Herne (DE)  
S. Brookman-May, Munich (DE)  
L. Budàus, Hamburg (DE)  
P. Carroll, San Francisco (US)  
E. Comperat, Paris (FR)  
C. Cozzarini, Milan (IT)  
G. De Meerleer, Ghent (BE)  
M. De Santis, Coventry (GB)  
F. Demichelis, Trento (IT)  
C. Dinney, Houston (US)  
J.I. Epstein, Baltimore (US)  
C. Evans, Sacramento (US)  
S. Falzarano, Cleveland (US)  
S. Fant, Bologna (IT)  
K. Fizazi, Villejuif (FR)  
P. Ghadjar, Berlin (DE)  
P. Gontero, Turin (IT)  
B. Hadaschik, Heidelberg (DE)  
A. Hartmann, Erlangen (DE)  
B. Haussler, Berlin (DE)  
P. Hoskin, Northwood (GB)  
B. Jereczek-Fossa, Milan (IT)  
S. Joniau, Leuven (BE)  
R.J. Karnes, Rochester (US)  
C. Kastner, Cambridge (GB)  
T. Klatte, Vienna (AT)  
L. Klotz, Toronto (CA)  
G. Kramer, Vienna (AT)  
M. Kruithof de Julio, Berne (CH)  
B. Ljungberg, Umea (SE)  
A. Lopez-Beltran, Lisbon (PT)  
Y. Loriot, Villejuif (FR)  
c. Magi-Galluzzi, Cleveland (US)  
G. Malouf, Paris (FR)  
G. Martignoni, Verona (IT)  
M. Mason, Cardiff (GB)  
J. Mischinger, Tübingen (DE)  
H. Moch, Zurich (CH)  
M. Mondini, Villejuif (FR)  
R. Montironi, Ancona (IT)  
F. Montorsi, Milan (IT)  
C. Moore, London (GB)  
S. Morgan, Sheffield (GB)  
N. Mottet, Saint-Étienne (FR)  
J. N'Dow, Aberdeen (GB)  
A. Necchi, Milan (IT)  
J. Oldenburg, Oslo (NO)  
S. Osanto, Leiden (NL)  
P. Ost, Ghent (BE)  
R. Oyen, Leuven (BE)  
V. Panebianco, Zurich (IT)  
W. Picker, Oslo (NO)  
P. Pierorazio, Baltimore (US)  
B. Pieters, Amsterdam (NL)  
M. Pinkawa, Aachen (DE)  
A. Ploumidis, Athens (GR)  
T. Powles, London (GB)  
M. Ritter, Mannheim (DE)  
D. Rosario, Sheffield (GB)  
O. Rouvière, Lyon (FR)  
R. Sanchez Salas, Paris (FR)  
K. Saeb-Parsey, Cambridge (GB)  
M. Schmidinger, Vienna (AT)  
G. Sonpavde, Birmingham (US)  
C.N. Sternberg, Rome (IT)  
C. Sweeney, Boston (US)  
G. Thalmann, Berne (CH)
B. Tombal, Brussels (BE)  
K. Touijer, New York (US)  
B. Van Cleynenbreugel, Leuven (BE)  
T. Van der Kwast, Toronto (CA)  
G. Van der Pluijm, Leiden (NL)  
H. Van der Poel, Amsterdam (NL)  
H. Van Poppel, Leuven (BE)  
J. Walz, Marseille (FR)  
T. Wiegel, Ulm (DE)  
M. Wirth, Dresden (DE)  
E. Xylinas, Paris (FR)

**ESUI Faculty**

H.U. Ahmed, London (GB)  
E. Baco, Oslo (NO)  
A. Briganti, Milan (IT)  
L. Budäus, Hamburg (DE)  
M.T.J. Bus, Amsterdam (NL)  
T. Cai, Trento (IT)  
N. Cowan, Portsmouth (GB)  
S. Fanti, Bologna (IT)  
M.X. Ferreira Coelho, Lisbon (PT)  
J.J. Futterer, Nijmegen (NL)  
P.A. Geavlete, Bucharest (RO)  
B. Geavlete, Bucharest (RO)  
F.L.G. Giesel, Heidelberg (DE)  
H. Gronberg, Stockholm (SE)  
B.A. Hadaschik, Heidelberg (DE)  
C. Kastner, Cambridge (GB)  
M. Kriegmair, Mannheim (DE)  
T. Loch, Flensburg (DE)  
T. Maurer, Munich (DE)  
N. Mottet, Saint-Étienne (FR)  
J. Neves, London (GB)  
I. Peters, Hannover (DE)  
A. Postema, Amsterdam (NL)  
M. Ritter, Mannheim (DE)  
G. Salomon, Hamburg (DE)  
R.E. Sanchez-Salas, Paris (FR)  
V. Scattoni, Milan (IT)  

G.N. Thalmann, Berne (CH)  
K. Touijer, New York (US)  
C. Trombetta, Trieste (IT)  
A. Vilaseca Cabo, Barcelona (ES)  
A. Villers, Lille (FR)  
J. Walz, Marseille (FR)  
H. Wijkstra, Amsterdam (NL)

**ESU Faculty**

A. Bergman, Amsterdam (NL)  
A. Bossi, Villejuif (FR)  
G. De Meerleer, Ghent (BE)  
P. Ost, Ghent (BE)  
J. Palou, Barcelona (SP)  
C. Sternberg, Rome (IT)  
H. Thoeny, Berne (CH)  
K. Touijer, New York (US)  
H. Van der Poel, Amsterdam (NL)

**YAU Faculty**

H. Borgmann, Frankfurt (DE)  
S. Brookman, Munich (DE)  
N. Buffi, Milan (IT)  
J-N.L. Cornu, Rouen (FR)  
J. Palou, Barcelona (ES)  
G. Ploussard, Toulouse (FR)  
F. Sanguedolce, London (GB)  
M. Sedelaar, Nijmegen (NL)  
M. S. Silay, Istanbul (TR)  
A-F. Spinoit, Ghent (BE)  
P. Verze, Naples (IT)  
E. Xylinas, Paris (FR)
5th Meeting of the EAU Section of Urological Imaging (ESUI)

Time: 08.30 - 18.20 hrs  
Location: Amber 1  
Costs: For registration costs, please see page 8  
Chair: J. Walz, Marseille (FR)

08.30 - 08.35  Welcome by the ESUI  
J. Walz, Marseille (FR)

08.35 - 10.30  Changing paradigms in prostate cancer diagnosis

Moderators:  
M. Ritter, Mannheim (DE)  
V. Scattoni, Milan (IT)  
J. Walz, Marseille (FR)

08.35 - 08.45  The way to targeted prostate biopsies in urology: A historical review  
T. Loch, Flensburg (DE)

08.45 - 09.10  Point and counterpoint discussion in prostate cancer diagnosis:  
MRI before primary biopsy - Let’s break the bank with the costs?  
Yes, indeed:  N. Mottet, Saint-Étienne (FR)  
No, not at all:  H.U. Ahmed, London (GB)

Discussion

09.10 - 09.25  Selection for prostate biopsy: Imaging vs. clinical criteria and biomarkers  
H. Gronberg, Stockholm (SE)

09.25 - 09.40  Prostate biopsy and sepsis: How to overcome the problem?  
T. Cai, Trento (IT)

09.40 - 09.55  Multiparametric ultrasound: What holds us back?  
A. Postema, Amsterdam (NL)

09.55 - 10.10  New ultrasound based technologies  
G. Salomon, Hamburg (DE)

10.10 - 10.25  Choose your weapons: Template perineal biopsy vs. fusion biopsy vs. systematic biopsy  
M. Ritter, Mannheim (DE)

10.25 - 10.30  Questions and answers

10.30 - 11.00  Coffee break
11.00 - 12.10  Replay session: Pre-recorded videos of how I do it

            T. Loch, Flensburg (DE)
            C. Trombetta, Trieste (IT)

11.00 - 11.10  MRI/US fusion biopsy: Cognitive
               J. Neves, London (GB)

11.10 - 11.20  MRI/US fusion biopsy: Image based navigation
               E. Baco, Oslo (NO)

11.20 - 11.30  MRI/US fusion biopsy: Mechanical navigation
               B.A. Hadaschik, Heidelberg (DE)

11.30 - 11.40  MRI/US fusion biopsy: Electromagnetic navigation
               C. Kastner, Cambridge (GB)

11.40 - 11.50  Multiparametric Ultrasound
               H. Wijkstra, Amsterdam (NL)

11.50 - 12.00  High frequency US
               J. Walz, Marseille (FR)

12.00 - 12.10  ANNA/C-TRUS
               I. Peters, Hannover (DE)

12.10 - 13.00  Lunch break and poster viewing

13.00 - 14.30  Molecular imaging in Urology: Joint session of ESUI and EANM

Moderators:  A. Briganti, Milan (IT)
             S. Fanti, Bologna (IT)
             B.A. Hadaschik, Heidelberg (DE)

13.00 - 13.25  The more you look, the more you find: Clinical consequences
               of new imaging technologies
               Prostate:  A. Briganti, Milan (IT)
               Bladder:  A. Vilaseca Cabo, Barcelona (ES)

Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.25 - 13.40</td>
<td>PSMA for initial staging: Benefit or waste of money?</td>
<td>L. Budäus, Hamburg (DE)</td>
</tr>
<tr>
<td>13.40 - 13.55</td>
<td>PSMA-PET/mpMR for detection of primary prostate cancer and implementation for fusion biopsy</td>
<td>F.L.G. Giesel, Heidelberg (DE)</td>
</tr>
<tr>
<td>13.55 - 14.10</td>
<td>PSMA-radioguided surgery for recurrent prostate cancer</td>
<td>T. Maurer, Munich (DE)</td>
</tr>
<tr>
<td>14.10 - 14.25</td>
<td>New PET-tracers on the horizon</td>
<td>S. Fanti, Bologna (IT)</td>
</tr>
<tr>
<td>14.25 - 14.30</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>14.30 - 15.15</td>
<td>Poster session and Best Poster Award</td>
<td>M.X. Ferreira Coelho, Lisbon (PT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P.A. Geavlete, Bucharest (RO)</td>
</tr>
<tr>
<td>14.30 - 14.40</td>
<td>Using patient screening data and machine learning algorithms to improve PRI-MUS™ accuracy</td>
<td>S. Ghai, Toronto (CA)</td>
</tr>
<tr>
<td></td>
<td>with micro-ultrasound-based prostate biopsies</td>
<td></td>
</tr>
<tr>
<td>14.40 - 14.50</td>
<td>Zirconium-89-girentuximab PET/CT imaging in renal cell carcinoma: First in man results</td>
<td>M. Hekman, Nijmegen (NL)</td>
</tr>
<tr>
<td>14.50 - 15.00</td>
<td>When to perform a staging chest-CT scan before surgical treatment for kidney cancer</td>
<td>U. Capitanio, Milan (IT)</td>
</tr>
<tr>
<td>15.00 - 15.10</td>
<td>Combining mpMRI sequences for the diagnosis of prostate cancer – the value of adding</td>
<td>J. Neves, London (GB)</td>
</tr>
<tr>
<td></td>
<td>diffusion and contrast enhancement to T2W on 3Tesla: Outcomes from the PICTURE trial</td>
<td></td>
</tr>
<tr>
<td>15.10 - 15.15</td>
<td>Best Poster Award</td>
<td></td>
</tr>
<tr>
<td>15.15 - 15.40</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>
Scientific programme - Thursday, 24 November

15.40 - 16.40  Improved imaging for urothelial cancer
   Moderators:  N. Cowan, Portsmouth (GB)
               B. Geavlete, Bucharest (RO)
               J. Walz, Marseille (FR)

15.40 - 15.55  The perfect “Uro-CT”: Do we also need standardisation?
   N. Cowan, Portsmouth (GB)

15.55 - 16.10  PDD vs. NBI vs. SPIES in bladder cancer
   B. Geavlete, Bucharest (RO)

16.10 - 16.25  OCT and confocal microscopy in urothelial cancer: Finally real
time histology?
   M.T.J. Bus, Amsterdam (NL)

16.25 - 16.35  Panoramic cystoscopy
   M. Kriegmair, Mannheim (DE)

16.35 - 16.40  Questions and answers

16.40 - 18.15  Changing paradigms in prostate cancer treatment
   Moderators:  J.J. Futterer, Nijmegen (NL)
               C. Kastner, Cambridge (GB)
               N. Mottet, Saint-Étienne (FR)

16.40 - 17.00  Point and counterpoint discussion in prostate cancer imaging: MRI
and active surveillance - No surveillance with MRI visible lesions?
   Surveillance is possible: J. Walz, Marseille (FR)
   Surveillance is discouraged: V. Scattoni, Milan (IT)

17.00 - 17.15  Image guided focal therapy, an alternative to whole gland treatment?
   G.N. Thalmann, Berne (CH)

17.15 - 17.30  Focal therapy: Treatment planning and follow-up
   R.E. Sanchez-Salas, Paris (FR)

17.30 - 17.45  MRI before radical prostatectomy: Benefit or waste of money?
   K. Touijer, New York (US)

17.45 - 18.00  How to train urologists to read a prostate MRI?
   A. Villers, Lille (FR)

18.00 - 18.15  What expertise is needed from a dedicated uro-radiologist?
   J.J. Futterer, Nijmegen (NL)

18.15 - 18.20  Summary and end of the ESUI programme
ESU course on ‘Challenging the last changes in the management of advanced and metastatic prostate cancer: Multidisciplinary approach’ at the occasion of the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 - 09.05</td>
<td>European School of Urology: A unique possibility for urological education</td>
</tr>
<tr>
<td>09.05 - 09.15</td>
<td>Current guidelines recommendations</td>
</tr>
<tr>
<td>09.15 - 09.55</td>
<td>Pelvic radiotherapy and local radiotherapy in metastasized disease</td>
</tr>
<tr>
<td>09.55 - 10.05</td>
<td>Discussion</td>
</tr>
<tr>
<td>10.05 - 10.45</td>
<td>Prostatectomy and lymphnode dissection in nodal metastasized prostate cancer</td>
</tr>
<tr>
<td>10.45 - 10.55</td>
<td>Discussion</td>
</tr>
<tr>
<td>10.55 - 11.10</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.10 - 11.50</td>
<td>Timing of chemotherapy in metastasized prostate cancer management</td>
</tr>
<tr>
<td>11.50 - 12.00</td>
<td>Discussion</td>
</tr>
<tr>
<td>12.00</td>
<td>Close</td>
</tr>
</tbody>
</table>

Chair: H. Van Der Poel, Amsterdam (NL)

Costs: For registration costs, please see page 8
**ESU course on ‘Multidisciplinary approach to the management of genito-urinary cancers: A clinical scenario based interactive session with the experts’ at the occasion of the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC)**

<table>
<thead>
<tr>
<th>Time:</th>
<th>Location:</th>
<th>Costs:</th>
<th>Panel:</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00 - 16.00 hrs</td>
<td>Amber 7</td>
<td>For registration costs, please see page 8</td>
<td>A. Bossi, Villejuif (FR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>P. Ost, Ghent (BE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J. Palou, Barcelona (ES)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C. Sternberg, Rome (IT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>H. Thoeny, Berne (CH)</td>
</tr>
</tbody>
</table>

13.00 - 14.00 **Prostate cancer – 3 clinical cases**

13.00 - 13.20 **Risk and prognosis assessment**  
- Clinically-based clinical models  
- Genomic-based clinical models  
- MRI and MRI fusion biopsy  
- Active surveillance  
- Indications of focal therapy

13.20 - 13.40 **High-risk and locally advanced**  
- Role of surgery in the multidisciplinary management  
- Role of radiation therapy in the multidisciplinary management  
- Salvage therapies for disease progression after primary therapy  
- Molecular imaging to guide therapy

13.40 - 14.00 **Metastatic prostate cancer**  
- Role of surgery and radiation therapy in the oligometastatic prostate cancer  
- Sequential vs. combination therapy: how to maximize benefit from hormonal agents  
- Resistance mechanisms to androgen pathway inhibitors  
- Role of chemotherapy as an early systemic therapy  
- Value of imaging in the decision-making

14.00 - 15.00 **Bladder cancer – 2 clinical cases**
14.00 - 14.30  Non-muscle invasive bladder cancer
   • Quality of TURBT
   • Molecular characterization of NIMBC
   • Intravesical therapy beyond BCG
   • Managing the heterogeneity of T1 urothelial carcinoma

14.30 - 15.00  Muscle invasive bladder cancer and systemic therapy
   • Quality metrics for radical cystectomy
   • Utilization of neoadjuvant chemotherapy a risk adjusted approach
   • Indications for and results of trimodal therapy
   • Novel combination therapies for bladder cancer
   • Genomic and prognosis of muscle invasive bladder cancer
   • Development of targeted agents

15.00 - 16.00  Kidney cancer – 2 clinical cases

15.00 - 15.30  Management of clinically localized renal cortical tumors
   • Role of needle biopsy in the era of molecular characterization
   • Role of active surveillance
   • Volume vs ischemia time in renal function recovery after partial nephrectomy
   • Medical vs. surgical chronic kidney disease
   • Value of nephrometry score
   • Managing the complication of partial nephrectomy

15.30 - 16.00  Advanced renal cell carcinoma
   • Novel systemic therapy including immunotherapy for the treatment of advanced RCC
   • Metastasectomy and cytoreductive nephrectomy in the targeted therapy era
   • Clarification on first and second line systemic therapy
   • Stereotactic radiation for metastases
   • Clinical application and usefulness of genomic characterization in renal cell carcinoma
**EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics (ESUP)**

**From the latest novelties to guidelines and protocols**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 - 17.30 hrs</td>
<td><strong>Welcome and introduction</strong>&lt;br&gt;By all chairs</td>
</tr>
<tr>
<td>Amber 5</td>
<td><strong>Latest novelties on the WHO morphological classifications of genitourinary cancers</strong>&lt;br&gt;Pathologist – J.I. Epstein, Baltimore (US)</td>
</tr>
<tr>
<td>15.10 - 15.40</td>
<td><strong>The 8th edition of the TNM staging (AJCC and UICC) of the genitourinary tumors: Implications from January 2017 and beyond</strong>&lt;br&gt;Pathologist – M. Amin, Los Angeles (US)</td>
</tr>
<tr>
<td>15.40 - 17.30</td>
<td><strong>Round Table: From morphology to personalised medicine in genitourinary cancers</strong></td>
</tr>
<tr>
<td>15.40 - 15.55</td>
<td><strong>Update on molecular pathology with clinical implications</strong>&lt;br&gt;Pathologist – H. Moch, Zurich (CH)</td>
</tr>
<tr>
<td>15.55 - 16.10</td>
<td><strong>How to translate advances in molecular pathology into clinical practice?</strong>&lt;br&gt;Urologist – B. Ljungberg, Umea (SE)</td>
</tr>
<tr>
<td>16.10 - 16.25</td>
<td><strong>Update on molecular pathology with clinical implications</strong>&lt;br&gt;Pathologist – C. Magi-Galluzzi, Cleveland (US)</td>
</tr>
<tr>
<td>16.25 - 16.40</td>
<td><strong>How to translate advances in molecular pathology into clinical practice?</strong>&lt;br&gt;Urologist – N. Mottet, Saint-Étienne (FR)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 16.40 - 16.55 | **Urothelial carcinoma**  
Update on molecular pathology with clinical implications  
Pathologist – A. Hartmann, Erlangen (DE) |
| 16.55 - 17.10 | **How to translate advances in molecular pathology into clinical practice?**  
Urologist – A. Necchi, Milan (IT) |
| 17.10 - 17.30 | Discussion |
| 17.30 | Close |
Hands-on Training (HOT)

The European School of Urology (ESU) has developed innovative and effective Hands-on-Training (HOT) courses, in partnership with the robotic (ERUS), uro-technology (ESUT) and imaging (ESUI) Sections, which offer practice and development of individual skills. Lively interaction among participants, faculty and tutors makes much of this work an effective and memorable way to gain and consolidate knowledge.

ESU/ERUS Hands-on Training in Robotic surgery - Intro course
The intro course consists of training and assessment of basic skills in a variety of exercises. There will be two intro Hands-on Training courses in Robotic surgery.

Time: 13.35 - 15.05 hrs
       15.45 - 17.15 hrs
Location: Amber 6
Costs: For registration costs, please see page 8
Course coordinator: H. Van Der Poel, Amsterdam (NL)
Tutor: A. Ploumidis, Athens (GR)

ESU/ESUT/ESUI Hands-on Training in MRI fusion biopsy
MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 5 different Fusion biopsy machines in small groups, changing every 10 min.

Time: 10.30 - 12.30 hrs
Location: Amber 8
Costs: For registration costs, please see page 8
Course coordinator: L. Budäus, Hamburg (DE)
Tutors: M. Brock, Herne (DE)
        B. Hadaschik, Heidelberg (DE)
        C. Kastner, Cambridge (GB)
        J. Mischinger, Tübingen (DE)
        W. Picker, Oslo (NO)
        M. Ritter, Mannheim (DE)
ESU/ESUT Hands-on training in Laparoscopy - Virtual procedural training

The course provides Hands-on training on VR haptic laparoscopic simulator for basic and advanced procedures. The modules include didactic step-by-step tutorials of the laparoscopic cholecystectomy and appendectomy, as well as free-hand compete procedure of Transperitoneal Laparoscopic Radical Left Nephrectomy.

Time: 09.15 - 10.45 hrs  
11.30 - 13.00 hrs  
13.35 - 15.05 hrs  
15.45 - 17.15 hrs

Location: Amber 3  
Costs: For registration costs, please see page 8  
Course coordinator: B. Van Cleynenbreugel, Leuven (BE)
### Scientific programme - Friday, 25 November

**8th European Multidisciplinary Meeting on Urological Cancers (EMUC)**

**Location:** Auditorium

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| **08.05 - 08.20** | Welcome and introduction                                | Medical oncologist – T. Powles (ESMO)  
Radiation oncologist – P. Hoskin (ESTRO)  
Urologist – H. Van Poppel (EAU)  
Radiologist – R. Oyen (ESUR)  
Pathologist – R. Montironi (ESUP) |
| **08.20 - 08.30** | ESU Online Education - Metastatic Prostate Cancer e-course | Urologist – N. Mottet, Saint-Étienne (FR)  
Urologist – J. Palou, Barcelona (ES) |
| **08.30 - 10.45** | Session 1: How to use combination therapies in prostate cancer | Medical oncologist – S. Osanto, Leiden (NL)  
Radiation oncologist – T. Wiegel, Ulm (DE)  
Urologist – M. Wirth, Dresden (DE) |
| **08.30 - 08.45** | How to optimize the use of adjuvant radiation therapy after radical prostatectomy: Integrating clinical and genomic features | Urologist – R. J. Karnes, Rochester (US) |
| **08.45 - 09.00** | What is the role of adjuvant systemic approaches after curative treatment? | Medical oncologist – K. Fizazi, Villejuif (FR) |
| **09.00 - 09.15** | What is the best multi-modal approach for node positive disease? | Urologist – K. Touijer, New York (US) |
| **09.15 - 09.30** | Salvage radiotherapy for locally recurrent disease: When and how? | Radiation oncologist – G. De Meerleer, Ghent (BE) |
| **09.30 - 09.45** | Discussion                                             |                                             |
| **09.45 - 10.00** | Oligo vs polymetastatic prostate cancer: Distinct tumor entities? | Urologist – A. Bjartell, Malmö (SE) |
| **10.00 - 10.15** | When to use chemotherapy in hormone sensitive prostate cancer | Radiation oncologist – M. Mason, Cardiff (GB) |
| **10.15 - 10.30** | Combined or sequential systemic treatment for castration resistant disease? | Medical oncologist – C. Sweeney, Boston (US) |
| **10.30 - 10.45** | Discussion                                             |                                             |
Scientific programme - Friday, 25 November

10.45 - 11.15  Coffee break and poster viewing

11.15 - 13.00  Session 2: Focus on uro-genital cancer variants
   Chairs:  Pathologist – E. Compérat, Paris (FR)
            Urologist – K. Touijer, New York (US)
            Medical oncologist – M. Schmidinger, Vienna (AT)

   **Prostate cancer**
   11.15 - 11.30  Variants of prostate cancer: The pathologist’s point of view
                  Pathologist – R. Montironi, Ancona (IT)
   11.30 - 11.45  Prostate cancer variants in the setting of mCRPCa and their clinical implications
                  Urologist – C. Evans, Sacramento (US)

   **Renal cell carcinoma**
   11.45 - 12.00  Variants of renal cell carcinoma: The pathologist’s point of view
                  Pathologist – G. Martignoni, Verona (IT)
   12.00 - 12.15  Variants of renal cell carcinoma: Clinical implications
                  Medical oncologist – G. Malouf, Paris (FR)

   **Bladder cancer**
   12.15 - 12.30  Variants of bladder cancer: The pathologist’s point of view
                  Pathologist – A. Lopez-Beltran, Lisbon (PT)
   12.30 - 12.45  Clinical implications of bladder cancer variants: The medical oncologist view
                  Medical oncologist – M. De Santis, Coventry (GB)

   12.45 - 13.00  Discussion

13.00 - 14.15  Lunch break and poster viewing

13.15 - 14.15  Industry session

14.15 - 14.30  When science meets the clinics: Genomic profiling in primary prostate cancer
               Medical oncologist – TBD

14.30 - 14.45  Best of Journals: Radiotherapy
               Chairs:  Radiation oncologist – B. Pieters, Amsterdam (NL)
                        Radiation oncologist – P. Ghadjar, Berlin (DE)
Scientific programme - Friday, 25 November

14.45 - 17.45 Session 3: Recurrent prostate cancer
Chairs:  Radiation oncologist – A. Bossi, Villejuif (FR)
         Radiation oncologist – M. Mason, Cardiff (GB)
         Urologist – H. Van Der Poel, Amsterdam (NL)

14.45 - 15.00 The genomic evolution of metastatic prostate cancer
Genetist – F. Demichelis, Trento (IT)

How to use imaging for the detection of clinical progression
15.00 - 15.15 The role of Multiparametric MRI
Radiologist – V. Panebianco, Zurich (IT)

15.15 - 15.30 The role of PET/CT: Which tracer for which patient?
Nuclear medicine physician – S. Fanti, Bologna (IT)

15.30 - 15.45 Evaluation of biopsies from sites of prostate cancer recurrence: A new standard?
Urological researcher – T. Van Der Kwast, Toronto (CA)

15.45 - 16.15 Coffee break and poster viewing

Imaging guided approaches for prostate cancer recurrences
16.15 - 16.30 When is surgery the best choice?
Urologist – S. Joniau, Leuven (BE)

16.30 - 16.45 The role of ablative radiotherapy: When and how
Radiation oncologist – B. Jereczek-Fossa, Milan (IT)

16.45 - 17.00 The role of focal therapy in the treatment of cancer recurrence
Urologist – R. Sanchez Salas, Paris (FR)

17.00 - 17.15 What is the value of imaging guided approaches in the era of early chemotherapy? The medical oncologist’s point of view
Medical oncologist – C.N. Sternberg, Rome (IT)

17.15 - 17.45 Discussion

17.45 - 18.45 Industry session
Hands-on Training (HOT)

The European School of Urology (ESU) has developed innovative and effective Hands-on Training (HOT) courses, in partnership with the robotic (ERUS), uro-technology (ESUT) and imaging (ESUI) Sections, which offer practice and development of individual skills. Lively interaction among participants, faculty and tutors makes much of this work an effective and memorable way to gain and consolidate knowledge.

ESU/ERUS Hands-on Training in Robotic surgery - Advanced virtual robotic procedural training

During the advanced course the trainee can practice partial and entire robotic procedures using the novel simulator software on the Robotix mentor. There will be two advanced virtual robotic procedural training courses.

Time:  09.30 - 11.00 hrs
      11.35 - 13.05 hrs
      14.05 - 15.35 hrs
Location: Amber 6
Costs:  For registration costs, please see page 8'
Course coordinator: H. Van Der Poel, Amsterdam (NL)
Tutor: A. Ploumidis, Athens (GR)

ESU/ESUT/ESUI Hands-on Training in MRI fusion biopsy

MRI is increasingly used in patients undergoing prostate biopsies. Different MRI Ultrasound fusion devices allow integrating the MRI information into the daily clinical workflow. The course will provide an overview on MRI reading, technical basics and different prostate biopsy approaches. Technical considerations, the transrectal or transperineal approach will be critically reviewed and discussed. During the second half of the course, the participants are able to try out 5 different Fusion biopsy machines in small groups, changing every 10 min.

Time:  09.00 - 11.00 hrs
Location: Amber 8
Costs:  For registration costs, please see page 8
Course coordinator: L. Budäus, Hamburg (DE)
Tutors:  S. Boxler, Berne (CH)
         M. Brock, Herne (DE)
         J. Mischinger, Tübingen (DE)
         W. Picker, Oslo (NO)
         K. Saeb-Parsy, Cambridge (GB)
ESU/ESUT Hands-on Training in Laparoscopy - Virtual procedural training
The course provides Hands-on Training on VR haptic laparoscopic simulator for basic and advanced procedures. The modules include didactic step-by-step tutorials of the laparoscopic cholecystectomy and appendectomy, as well as free-hand compete procedure of Transperitoneal Laparoscopic Radical Left Nephrectomy.

Time: 09.30 - 11.00 hrs
11.30 - 13.00 hrs
13.30 - 15.00 hrs

Location: Amber 3

Costs: For registration costs, please see page 8

Tutor: B. Van Cleynenbreugel, Leuven (BE)
FALCON contouring workshop

Salvage intraprostatic relapses

Time: 09.00 - 10.45 hrs
Location: Amber 2
Costs: For registration costs, please see page 8
Workshop leaders and panelists: A. Bossi, Villejuif (FR), B. Pieters, Amsterdam (NL), B. Jereczek, Milan (IT)

Contouring workshops
ESTRO organised contouring workshops in the last two editions of the EMUC conference on the following topics:
- Hands on Training (HOT) Prostate radiotherapy delineation contouring workshop, at the 6th EMUC meeting in 2014
- A delineation contouring workshop on IRM-based delineation in prostate cancer treatment with focus on focal therapy, at the 7th EMUC meeting in 2015.

Both workshops were attended by over 20 people.
On the occasion of the 8th EMUC meeting, ESTRO is organizing a delineation contouring workshop on the topic: Salvage intraprostatic relapses.

Target audience
The delineation workshops are aimed at junior clinical or radiation oncologists wanting to improve their contouring skills or more senior specialists wanting to refresh and validate their knowledge and skills in this field.

Structure of the workshops
• Explanation of the contouring software
• Presentation of the clinical case
• 1st round of contouring (20 minutes)
• Presentation of the delineation guidelines
• 1st round of contouring (15 minutes)
• Discussion between experts and participants

FALCON (Fellowship in Anatomic delineation and CONtouring) is the multifunctional ESTRO platform for contouring and delineation. Attending a FALCON workshop offers the opportunity for individual professionals to validate their contouring practice during live workshops by comparing them with those from experts and other participants to learn the indications proposed by the experts that coordinate the workshops to discuss with other participants, experts and panellists to communicate and use the delineation guidelines in order to further integrate themselves into daily practice.
Uropathology training workshop for clinicians

Joint histological evaluation of the prostate, bladder and kidney specimens by the uropathologist and the clinician: Together, we can do it better.

Time: 13.15 - 14.15 hrs
Location: Amber 1
Costs: Free of charge (NOTE: Registration for this workshop is mandatory)
Workshop leaders and panelists:
- R. Montironi, Ancona (IT)
- A. Lopez-Beltran, Lisbon (PT)
- S. Morgan, Sheffield (GB)

Aims
The joint histological evaluation of specimens by the clinician and uropathologist can produce much more clinical and prognostic information than that contained in the final histopathology report. Both the clinician and uropathologist can benefit from such an approach. The former will more clearly understand and explain the preoperative features of the cancer, the intraoperative findings, and postoperative follow-up of the patient. The experience acquired would help improve him/her diagnostic and prognostication capabilities and surgical skill. The uropathologist will learn the great clinical significance of his/her daily routine.

Description
The workshop will be based on the projection and discussion of virtual slides of prostate, bladder and kidney tumors. In particular, the workshop will focus on the recently updated World Health Organization (WHO) classification of prostate, bladder and kidney tumors, including the re-classification of some previously recognized tumors and the additional of new subtypes that were not included in the prior 2004 WHO classification.

Join the workshop to:
- Become aware of recent changes made to the WHO classification of prostate, bladder and kidney epithelial tumors;
- Understand how to use morphologic clues in diagnosing prostate, bladder and kidney tumors
- Understand how to approach the use of biomarkers for evaluating various subtypes of prostate, bladder and kidney
Scientific programme - Saturday, 26 November

8th European Multidisciplinary Meeting on Urological Cancers (EMUC)

Location: Auditorium

09.00 - 10.45 Session 4: Kidney cancer: From diagnosis to progression
Clinical case presentation with multidisciplinary discussion
Chairs: Pathologist – A. Lopez-Beltran, Lisbon (PT)
Medical oncologist – L. Albiges, Villejuif (FR)
Urologist – A. Bex, Amsterdam (NL)

09.00 - 09.15 A case of 3.5 cm tumor
Urologist – T. Klatte, Vienna (AT)

09.15 - 09.30 The role of surveillance
Urologist – P. Pierorazio, Baltimore (US)

09.30 - 09.45 Partial nephrectomy: Whenever possible?
Urologist – H. Van Poppel, Leuven (BE)

09.45 - 10.00 The role of morphology and molecular pathology
Urological researcher – M. Amin, Los Angeles (US)

10.00 - 10.15 Follow up in kidney cancer
Urologist – A. Alcaraz, Barcelona (ES)

10.15 - 10.30 Metastatic disease
Medical oncologist – T. Powles, London (GB)

10.30 - 10.45 Discussion

10.45 - 11.15 Coffee break and poster viewing

11.15 - 11.55 Oral presentations of the 6 best abstracts
Chairs: Medical oncologist – A. Necchi, Milan (IT)
Urologist – M. Wirth, Dresden (DE)

11.55 - 12.10 Lecture: The role of micro-environment in GU cancers
Chair: Urologist – A. Briganti, Milan (IT)
Speaker: Biochemist – G. Van Der Pluijm, Leiden (NL)
12.10 - 13.00  **A focus on consequences of pelvic radiotherapy**  
Chairs: Radiation oncologist – P. Hoskin, Northwood (GB)  
Urologist – G. Thalmann, Berne (CH)

12.10 - 12.30  **Pelvic radiation disease: From pathophysiology to therapy**  
Radiation oncologist – M. Pinkawa, Aachen (DE)

12.30 - 12.40  **The risk of secondary cancers: An under-reported clinical scenario?**  
Radiation oncologist – C. Cozzarini, Milan (IT)

12.40 - 12.50  **Immune effects of pelvic radiotherapy**  
M. Mondini, Villejuif (FR)

12.50 - 13.00  **Discussion**

13.00 - 14.15  **Lunch break and poster viewing**

13.15 - 14.15  **Industry session**

14.15 - 14.30  **Update on adjuvant therapies in high risk kidney cancer. Results from phase 3 trials and future perspectives**  
Speaker: Urologist – A. Bex, Amsterdam (NL)

14.30 – 14.40  **Announcement 3 best unmoderated posters**  
Chairs: Urologist – A. Briganti, Milan (IT)  
Urologist – S. Brookman-May, Munich (DE)

14.40 – 15.00  **The role of Progenitor cells and organoids in the translational research of prostate cancer**  
Chair: Medical oncologist – S. Osanto, Leiden (NL)  
Speaker: Scientist – M. Kruithof de Julio, Berne (CH)

15.00 - 15.15  **Best of journals: Surgery**  
Chairs: Urologist – F. Montorsi, Milan (IT)  
Urologist – J. Walz, Marseille (FR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
</table>
| 15.15 - 16.40 | **Session 5: High grade bladder Cancer: From diagnosis to progression**  
**Clinical case presentation with multidisciplinary discussion**  
*(Case presentation T1 high grade by YAU)*  
*Chairs: Radiation oncologist – P. Ost, Ghent (BE)*  
*M. Medical oncologist – C. Sternberg, Rome (IT)*  
*Urologist – TBC* |
| 15.15 - 15.25 | **Case presentation**  
*Urologist – E. Xylinas, Paris (FR)* |
| 15.25 - 15.40 | **Pathology: Are all T1 high grade created equal?**  
*Pathologist – E. Compérat, Paris (FR)* |
| 15.40 - 15.55 | **How to minimize the side effects of radical cystectomy**  
*Urologist – J. Bedke, Tübingen (DE)* |
| 15.55 - 16.10 | **How to optimize patient selection for neoadjuvant chemotherapy**  
*Urologist – C. Dinney, Houston (US)* |
| 16.10 - 16.25 | **Adjuvant chemotherapy**  
*Medical oncologist – G. Sonpavde, Birmingham (US)* |
| 16.25 – 16.40 | **Immunotherapy in advanced urothelial carcinoma**  
*Oncologist – Y. Loriot, Villejuif (FR)* |
| 16.40 - 17.00 | **Coffee break and poster viewing** |
| 17.00 - 17.45 | **Session 6: Sports and lifestyle in uro-oncology**  
*Chairs: Urologist – S. Brookman-May, Munich (DE)  
*Urologist – H. Van Poppel, Leuven (BE)* |
| 17.00 - 17.15 | **Role of physical activity, sports and lifestyle in oncology – does it impact cancer incidence, oncological outcome and quality of life?**  
*Urologist – D. Rosario, Sheffield (GB)* |
| 17.15 - 17.30 | **Physiopathological impact on lifestyle on prostate health, inflammation and carcinogenesis**  
*Urologist – M. Albersen, Leuven (BE)* |
| 17.30 - 17.45 | **Discussion** |
| 17.45 - 18.45 | **Industry session** |
Meeting of the Young Academic Urologists

Time: 08.30 - 16.00 hrs
Location: Brown 1

Moderators plenary session: M. Sedelaar, Nijmegen (NL)
M. S. Silay, Istanbul (TR)

08.30 - 08.45 YAU Overview and welcoming new members
M. S. Silay, Istanbul (TR)

08.45 - 09.15 YAU Working parties reports (3 min each)
Renal Cancer; S. Brookman, Munich (DE)
Prostate Cancer; G. Ploussard, Toulouse (FR)
Urothelial Cancer; E. Xylinas, Paris (FR)
Endourology-Stone Disease; F. Sanguedolce, London (GB)
Pediatrics; A-F. Spinoit, Ghent (BE)
Men’s Health; P. Verze, Naples (IT)
Functional Urology; J-N.L. Cornu, Rouen (FR)
ERUS-Robotic; N. Buffi, Milan (IT)

09.15 - 09.30 How to improve the contribution of YAU in ESU activities
J. Palou, Barcelona (ES)

09.30 - 09.45 Social Media in Urology: A new platform for YAU?
H. Borgmann, Frankfurt (DE)

09.45 - 10.00 Coffee break

10.00 - 10.45 Interactive discussion with YAU members

10.45 - 16.00 Brainstorming of YAU working groups
8th European Multidisciplinary Meeting on Urological Cancers (EMUC)

Location: Auditorium

09.15 - 09.25 Announcement 3 best unmoderated posters
Chairs: Medical oncologist – J. Oldenburg, Oslo (NO)
       Urologist – J. Walz, Marseille (FR)

09.25 - 09.40 Best of journals: Medical oncology
Chairs: Medical oncologist – M. De Santis, Coventry (GB)
       Medical oncologist – J. Oldenburg, Oslo (NO)

09.40 - 11.00 Session 7: Improving active surveillance protocols in prostate cancer
Chairs: Urologist – C. Bangma, Rotterdam (NL)
       Urologist – F. Montorsi, Milan (IT)
       Radiologist – O. Rouvière, Lyon (FR)

09.40 - 09.55 Active Surveillance for Early Stage Prostate Cancer – More Restrictive or Less? The Impact of New Technology.
Summary of the 2016 ESO meeting
Urologist – P. Carroll, San Francisco (US)

09.55 - 10.10 Role of MRI in active surveillance: Strengths and limitations
Urologist – C. Moore, London (GB)

10.10 - 10.25 Pathology and genomics for active surveillance
Pathologist – S. Falzarano, Cleveland (US)

10.25 - 10.40 Is active surveillance justifiable in 3+4 cancers (prognostic grade group 2)?
Urologist – L. Klotz, Toronto (CA)

10.40 - 11.00 Discussion

11.00 - 11.20 Personalized medicine and health economics: How can expensive personalized medicine finally be profitable to health economics
Chair: Medical oncologist – M. Schmidinger, Vienna (AT)
Speaker: Medical doctor/sociologist – B. Häussler, Berlin (DE)

11.20 - 11.30 EU joint action on cancer control – improving prostate cancer diagnosis and care
Speaker: Health system researcher – T. Albreht, Ljubljana (SI)
Scientific programme - Sunday, 27 November

11.30 - 12.20  Take home messages
11.30 - 11.40  Radiologist - R. Oyen, Leuven (BE)
11.40 - 11.50  Urologist - A. Briganti, Milan (IT)
11.50 - 12.00  Medical oncologist - S. Osanto, Leiden (NL)
12.00 - 12.10  Radiation oncologist - B. Jereczek-Fossa, Milan (IT)
12.10 - 12.20  Pathologist - R. Montironi, Ancona (IT)

12.20 - 12.30  Closing remarks
Medical oncologist - M. Schmидinger (ESMO)
Radiation oncologist - P. Hoskin (ESTRO)
Urologist - H. Van Poppel (EAU)
About the Organisers

The European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology, with the overarching goal of improving outcomes for cancer patients everywhere. We are the society of reference for oncology education and information, and are committed to supporting our members to develop and advance in a fast-evolving professional environment.

Founded in 1975, ESMO has European roots with a global reach: we welcome oncology professionals from around the world. We are a home for all oncology stakeholders, connecting professionals with diverse expertise and experience, and speaking with one voice for our discipline. Our education and information resources support an integrated multi-professional approach to cancer care, from a medical oncology perspective. We seek to erase boundaries in cancer care, whether between countries or specialities, and pursue our mission across oncology, worldwide.

The ESMO community brings together about 14,000 oncology professionals from over 130 countries. Drawing on 40 years of experience and around 500 expert committee members, ESMO serves its members and the oncology community through:

- Post-graduate oncology education and training
- Career development and leadership training for the next generations of oncologists
- International congresses and workshops to share expertise and best practice, learn about the most up-to-date scientific advances, and connect with colleagues in related disciplines worldwide.
- Continuously reviewed, evidence-based standards for cancer care in Europe
- Advocacy and consultation to foster a favourable environment for scientific research

ESMO Faculty offers a full range of post-graduate oncology education, along with online information resources and scientific journals. We foster the next generation of oncologists by providing career development and leadership training programmes. Our leading experts develop guidelines to define best clinical practice and support optimal care for cancer patients across Europe. We establish joint projects with cancer organisations to support closer integration of research, diagnostic, and clinical expertise. We speak for oncology in consultation with national, European, and international authorities, advocating for excellence in cancer research, evidence-based decision-making, and equal access to optimal care for patients. We bring together oncology professionals at international congresses and courses to share expertise and make new contacts.
As a globally growing society, ESMO gives oncology professionals worldwide a solid platform to support optimal care for their patients. Cancer care is rapidly becoming more integrated and more specialised; whether their field is research, diagnosis, treatment, care, or advocacy, professionals need to both build their specialist knowledge and connect with the best practitioners in other disciplines worldwide. ESMO membership makes this possible.

Please visit www.esmo.org to learn more. Across Oncology. Worldwide.
About the Organisers

The European Society for Radiotherapy and Oncology (ESTRO)

Founded in 1980, the European Society for Radiotherapy and Oncology, ESTRO, is a non-profit, scientific organisation whose role is to foster, in all its aspects, radiation oncology, clinical oncology and related subjects, including physics as applied to radiotherapy, radiation technology and radiobiology.

To fulfill its purpose, ESTRO:
• Develops and promotes standards of education in radiotherapy and clinical oncology
• Promotes standards of practice in radiotherapy, clinical oncology and related subjects
• Stimulates the exchange of scientific knowledge in all related fields
• Strengthens the clinical specialty of radiotherapy and clinical oncology in relation to other specialties and professions involved in cancer management
• Encourages co-operation with international, regional and national societies and bodies representing radiotherapy, clinical oncology and related subjects
• Facilitates research and development in radiotherapy, clinical oncology and related subjects.

2017 ESTRO membership
ESTRO is devoted to advancing the goals of radiation oncology. This includes providing its members with outstanding science and education in order to support them in their career advancement.

2017 ESTRO membership is available and offers numerous services:
• Subscription to Radiotherapy & Oncology,
• Discount on the article publication charge related to the new open access journals: Clinical & Translational Oncology (ctRO), Physics & Imaging in Radiation Oncology (phiRO) and Technical Innovations & Patient Support in Radiation Oncology (tipsRO)
• Reduced fees for attending ESTRO conferences, teaching courses and joint events
• Online access to scientific material (events webcasts, delineation cases, etc) through the e-library (DOVE)
• Eligibility for grants, awards, faculties and governance positions
• And much more.

Individual Membership:
Full members:
• Active (€95 for 1 year or €170 for 2 consecutive years)
• Supporting Ambassador (€250 for 1 year or €450 for 2 consecutive years)
Associate members:
• In Training (€75)
• Affiliate (€55)
• Corporate Representative (€55)
Online registration on www.estro.org/members.

Institutional Membership:
ESTRO offers European institutes the possibility to pay collectively for the membership of their employees (minimum of 5), who will enjoy all the usual advantages of the individual membership. This is the most cost-effective option for institutes who will also benefit from a host of advantages such as a dedicated promotional webpage on the ESTRO website and in the newsletter, a monthly ESTRO public affairs newsletter exclusively tailored to their needs, and the privilege to apply for a free exhibiting booth at the annual event (Communities Pavilion).

More info on estro.org/members. To register, please contact institutional-membership@estro.org.

ESTRO conferences
Next ESTRO conferences

6th ICHNO (International Conference on innovative approaches in Head and Neck Oncology)
16-18 March 2017, Barcelona, Spain

ESTRO 36
5-9 May 2017, Vienna, Austria

5th GEC-ESTRO Workshop
1 December 2017, Rome, Italy

Meeting in scientific collaboration
ECCO 2017- European Cancer Congress: From Evidence to Practice in Multidisciplinary Cancer Care
27-30 January 2017 | Amsterdam, The Netherlands

With 2 ESTRO Workshops on 27 January 2017:
• Towards state-of-the-art radiotherapy for every cancer patient: What is at stake?
• Communication in Oncology
About the Organisers

ESTRO School
The ESTRO School is recognised internationally to provide high-quality education in multidisciplinary oncology and offers a wide range of activities:
• Live teaching courses: in 2017, 36 courses will be organised mostly in Europe and beyond that will attract 3,000 participant
• e-learning tools have been developed in order to extend and coordinate teaching resources worldwide:
  - FALCON (Fellowship in Anatomic deLineation and CONtouring): ESTRO’s delineation tool
  - DOVE (Dynamic Oncology Virtual ESTRO): e-library giving access to educational and scientific material such as articles, conference abstracts, webcasts, e-posters, slides, contouring cases, guidelines,..

Calendar of the 2017 live teaching courses

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
<th>Location</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 5-8</td>
<td>Comprehensive and practical brachytherapy</td>
<td>Budapest</td>
<td>Hungary</td>
</tr>
<tr>
<td>March 6-10</td>
<td>Particle Therapy</td>
<td>Essen</td>
<td>Germany</td>
</tr>
<tr>
<td>March 8-11</td>
<td>Transition from conventional 2D to 3D RT with a special emphasis on BT in cervical cancers</td>
<td>Bengaluru</td>
<td>India</td>
</tr>
<tr>
<td>March 22-24</td>
<td>Lower GI: Technical and clinical challenges for radiation oncologists</td>
<td>Rome</td>
<td>Italy</td>
</tr>
<tr>
<td>March 25-28</td>
<td>Upper GI: Technical and clinical challenges for radiation oncologists</td>
<td>Rome</td>
<td>Italy</td>
</tr>
<tr>
<td>April 2-6</td>
<td>Dose modelling and verification for external beam radiotherapy</td>
<td>Warsaw</td>
<td>Poland</td>
</tr>
<tr>
<td>April 9-13</td>
<td>IMRT and other conformal techniques in practice</td>
<td>Madrid</td>
<td>Spain</td>
</tr>
<tr>
<td>April 10-13</td>
<td>ESTRO/ESNM course on molecular imaging and radiation oncology</td>
<td>Bordeaux</td>
<td>France</td>
</tr>
<tr>
<td>May 21-23</td>
<td>Cancer Survivorship</td>
<td>Brussels</td>
<td>Belgium</td>
</tr>
<tr>
<td>May 21-25</td>
<td>Multidisciplinary management of prostate cancer</td>
<td>Porto</td>
<td>Portugal</td>
</tr>
<tr>
<td>June 2-4</td>
<td>ESTRO-KOSRO GI: Technical and clinical challenges for radiation oncologists</td>
<td>Seoul</td>
<td>South Korea</td>
</tr>
<tr>
<td>June 4-8</td>
<td>Physics for modern radiotherapy</td>
<td>Bucharest</td>
<td>Romania</td>
</tr>
<tr>
<td>June 11-15</td>
<td>Advanced skills in modern radiotherapy</td>
<td>Prague</td>
<td>Czech Rep</td>
</tr>
<tr>
<td>June 11-16</td>
<td>Evidence Based Radiation Oncology</td>
<td>Ljubljana</td>
<td>Slovenia</td>
</tr>
<tr>
<td>June 15-18</td>
<td>Combined drug-radiation treatment: biological basis, current applications and perspectives</td>
<td>Milan</td>
<td>Italy</td>
</tr>
<tr>
<td>June 25-28</td>
<td>Target volume determination - From imaging to margins</td>
<td>Lisbon</td>
<td>Portugal</td>
</tr>
<tr>
<td>June 29- July 1</td>
<td>Brachytherapy for prostate cancer</td>
<td>Brussels</td>
<td>Belgium</td>
</tr>
<tr>
<td>July 5-9</td>
<td>Comprehensive quality management in radiotherapy</td>
<td>Chengdu</td>
<td>China</td>
</tr>
<tr>
<td>Sept 3-7</td>
<td>Advanced treatment planning</td>
<td>Barcelona</td>
<td>Spain</td>
</tr>
<tr>
<td>Date</td>
<td>Event</td>
<td>Location</td>
<td>Country</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Sept 3-7</td>
<td>Clinical practice and implementation of image-guided stereotactic body radiotherapy</td>
<td>Budapest</td>
<td>Hungary</td>
</tr>
<tr>
<td>Sept 7-9</td>
<td>Palliative care and radiotherapy</td>
<td>Brussels</td>
<td>Belgium</td>
</tr>
<tr>
<td>Sept 10-13</td>
<td>Multidisciplinary management of breast cancer</td>
<td>Dublin</td>
<td>Ireland</td>
</tr>
<tr>
<td>Sept 10-13</td>
<td>Research Masterclass in Radiotherapy Physics</td>
<td>Florence</td>
<td>Italy</td>
</tr>
<tr>
<td>Sept 16-20</td>
<td>Basic clinical radiobiology</td>
<td>Paris</td>
<td>France</td>
</tr>
<tr>
<td>Oct 2-5</td>
<td>Comprehensive quality management in radiotherapy - quality assessment and improvement</td>
<td>Brussels</td>
<td>Belgium</td>
</tr>
<tr>
<td>Oct 8-11</td>
<td>Quantitative methods in radiation oncology: models, trials and clinical outcomes</td>
<td>Maastricht</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Oct 16-18</td>
<td>Best practice in radiation oncology - Train the RTT (Radiation Therapists) Trainers</td>
<td>Vienna</td>
<td>Austria</td>
</tr>
<tr>
<td>Oct 22-24</td>
<td>Multidisciplinary management of brain tumours</td>
<td>Vienna</td>
<td>Austria</td>
</tr>
<tr>
<td>Oct 22-26</td>
<td>Image-guided radiotherapy and chemotherapy in gynaecological cancer: focus on MRI adaptive brachytherapy</td>
<td>Prague</td>
<td>Czech Rep</td>
</tr>
<tr>
<td>Oct 29 - Nov 2</td>
<td>Image guided radiotherapy in clinical practice</td>
<td>Athens</td>
<td>Greece</td>
</tr>
<tr>
<td>Nov 2-3</td>
<td>ESTRO-ESOR: Multidisciplinary approach of cancer imaging</td>
<td>Rome</td>
<td>Italy</td>
</tr>
<tr>
<td>Nov 5-9</td>
<td>Imaging for physicists</td>
<td>Malaga</td>
<td>Spain</td>
</tr>
<tr>
<td>Nov 30 - 2 Dec</td>
<td>Paediatric radiotherapy</td>
<td>Brussels</td>
<td>Belgium</td>
</tr>
<tr>
<td>Dec 9-13</td>
<td>Multidisciplinary management of head and neck oncology</td>
<td>Singapore</td>
<td>Singapore</td>
</tr>
</tbody>
</table>

**Undergraduate training for medical students**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Location</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 10-21</td>
<td>Medical Science Summer School Oncology For Medical Students</td>
<td>Vienna</td>
<td>Austria</td>
</tr>
<tr>
<td>Aug 28 - Sept 8</td>
<td>ESO-ESSO-EESTRO Multidisciplinary Course In Oncology For Medical Students</td>
<td>Antwerp</td>
<td>Belgium</td>
</tr>
</tbody>
</table>
About the Organisers

The European Association of Urology (EAU)

Founded in 1972, the European Association of Urology (EAU) represents the leading authority within Europe on urological practice, research and education. Over 15,000 medical professionals have joined its ranks and contribute to our mission: To raise the level of urological care throughout Europe and beyond.

With the goal to create a dynamic network, the EAU supports medical professionals active in the field of urology through many of its scientific, professional, educational and awareness-building initiatives:

• **Career Development**
  Whether you are a resident, a young urologist or an experienced specialist, the EAU supports urologists throughout their career with programmes for continuing medical education and certification. We offer several educational programmes developed by the European School of Urology (ESU), scholarships and clinical visits. One of the most important tools to continue your professional development is UROsource, the EAU learning library for urologists. With over 50,000 items of scientific content it is the single largest knowledge base available today in the field of urology.

• **Clinical Guidelines**
  For any successful clinician, having the most up-to-date evidence-based recommendations on hand is crucial for the successful treatment of your patients. The EAU Guidelines are unparalleled in that regard and used all across the world. They are comprehensively updated on an annual basis and freely accessible for all members.

• **Political Activities**
  Urologists are bound by national and, increasingly, international laws that govern treatment options and patient care. The EAU brings together the voices of medical professionals, researchers, innovators and patients on a European platform to keep urological topics on the agendas of the authorities.

• **Networking with Peers**
  The EAU offers a wide range of events and courses to interact with the best specialists in the field of urology. The Annual EAU Congress is the largest urology-related event in the world where you can network with like-minded professionals.
• **Advancing Urological Science**
  
  Our journal, European Urology, has been a prestigious urological forum for over 35 years, and is currently read by more than 20,000 urologists. It is one of the most widely-cited medical journals in the world and, with an impact factor of 14.976 leading in its field. Members have free access to full-text articles. The second official publication of the EAU is European Urology Focus (EU Focus), the new sister journal to European Urology. Each issue will include a series of invited, thematic reviews, together with original reports, correspondence and introductory editorials on a wide range of urological issues.

If you are interested in joining the largest international urological community in Europe, please visit www.uroweb.org/membership and find out what other benefits the EAU membership has to offer.
About the Organisers

The European School of Urology (ESU)

The European School of Urology (ESU), on behalf of the EAU Education Office, responds to the education and training needs of urologists. Through various activities, the ESU stimulates, coordinates and organises all post-graduate teaching, education and hands-on training offered by the EAU.

With the ESU’s focus on knowledge-sharing and skills development, it provides support to doctors at any stage of their career in urology and to allied medical professionals. To enhance and facilitate the learning experience, the ESU employs both online technology and traditional teaching methods in its courses offered during the Annual EAU Congress and accredited meetings. This makes the ESU a front-line educational resource for professionals in urology. Over 16,000 medical professionals, world-wide, benefit from the ESU’s activities and projects, contributing to forward-looking solutions in medical education and professional growth.

The ESU’s success is anchored on the continued support of the ESU faculty, a community of 150 opinion leaders and experts in various urological specialties. They invest their time and expertise to all teaching activities on a voluntary basis, and we are grateful for their commitment to improve medical education and contribute to the progress of international urology.

To learn more about the European School of Urology, visit www.uroweb.org/education or contact the ESU at esu@uroweb.org.

ESU Board
J. Palou, Barcelona (ES) - Chairman
J. Angulo, Madrid (ES)
T. Bach, Hamburg (DE)
M. Babjuk, Prague (CZ)
M.J. Drake, Bristol (GB)
E. Liatsikos, Patras (GR)
O. Traxer, Paris (FR)
B.S.E.P. Van Cleynenbreugel, Leuven (BE)
H.G. Van Der Poel, Amsterdam (NL)
R.J.A. Van Moorselaar, Amsterdam (NL)
J. Rassweiler, Heilbronn (DE)
H. Van Poppel, Leuven (BE) - Ex-Officio
About the Organisers

The EAU Section of Urological Imaging (ESUI)

The ESUI, a section of the European Association of Urology, aims to increase the knowledge and integrate the know-how on imaging techniques among urologists. With its emphasis on multidisciplinary strategies and goal to improve collaboration with related specialities and affiliates, including radiologists and nuclear medicine physicians, the ESUI offers various activities to its members and other urological professionals.

To complement the EAU’s scientific and educational initiatives, the ESUI organises courses and training during its meetings and participates in the EAU’s broader educational strategies. Over the years, the ESUI’s membership has steadily expanded and its long-term strategies include knowledge-sharing with organisations and specialists groups not only within the urological community but also with other medical disciplines.

Activities
The ESUI organises meetings to present urological imaging at different podia in Europe on a regular basis. One of the main platforms is its annual meeting held in various European cities. These meetings address controversial issues in urology, particularly new developments and challenges in urological imaging, its role in optimal diagnostic and treatment modalities, and the exchange of know-how among the international experts.

Further on, the ESUI is organizing and endorsing clinical trials that evaluate urological imaging in clinical settings. They also organise surveys that address current issues and controversies on a European level. Finally the ESUI is also active in the EAU guidelines process by providing expertise in urological imaging.

ESUI Board
ESUI Chairman Dr. Jochen Walz, Marseille (FR)
ESUI Board Dr. Hashim Uddin Ahmed, London (GB)
ESUI Board Dr. Brendan Carey, Leeds (GB)
ESUI Board Ass. Prof. Manuel Xavier Ferreira Coelho, Lisbon (PT)
ESUI Board Prof. Petrisor Aurelian Geavlete, Bucharest (RO)
ESUI Board Prof. Tillmann Loch, Flensburg (DE)
ESUI Board Dr. Georg Salomon, Hamburg (DE)
ESUI Board Dr. Vincenzo Scattoni, Milan (IT)
ESUI Board Prof. Dr. Hessel Wijkstra, Amsterdam (NL)
Ex YAU Office Dr. Jurgen Futterer, Nijmegen (NL)
The Young Academic Urologists (YAU)

The Young Academic Urologists (YAU) is a group of talented and renowned European young urologists (<40 years old), established few years ago by the EAU as a branch of the Young Urologists Office (YUO). Members are rigorously selected according to their scientific, clinical and surgical skills; currently, almost 100 members have joined the YAU, working within one the 9 subgroups according to their field of expertise.

Mission

YAU’s aims are: to promote high-quality studies in order to provide strong evidence for the best urological practice; to promote educational programmes in order to boost European training standards; to create a platform for close international cooperation for the future urology leaders in Europe.

Activities

In the last few years several high quality publications have been promoted, developed and issued by the YAU members as a result of the close and effective relationship between the scientists and centres involved. Strategic partnerships have been developed with other EAU bodies like the Guidelines Office, the Sections Office and the European School of Urology; as a result, several projects have been successfully finalised in support or in collaboration with the relevant partners.

YAU Board

M.S. Silay, Istanbul (TR) (Chair & Working group Paediatric Urology)
S.D. Brookman-May, Munich (DE) (Working group Renal Cell Carcinoma)
N. Buffi , Milan (IT) (Working group Robotic in Urology)
J-N. Cornu, Rouen (FR) (Working group Functional Urology)
G. Ploussard, Toulouse (FR) (Working group Prostate Cancer)
F. Sanguedolce, London (GB) (Working group Endourology & Urolithiasis)
P. Verze, Naples (IT) (Working group Men’s Health)
E. N. Xylinas, Paris (FR) (Working group Urothelial)
Friday, 25 November

Location: Auditorium

13.15 - 14.15   Incorporating a new treatment in advanced RCC: the evolving role of TKIs
13.15 - 13.20   Welcome
                C.N. Sternberg, Rome (IT)
13.20 - 13.35   From cytokines to targeted therapies: 20 years of progress in advanced RCC
                T. Powles, London (GB)
13.35 - 13.50   Overcoming TKI resistance in advanced RCC
                C.N. Sternberg, Rome (IT)
13.50 - 14.05   Guidelines in RCC: How evidence-based recommendations serve as a guide for clinical decisions
                A. Bex, Amsterdam (NL)
14.05 - 14.15   Panel discussion and close
Friday, 25 November

Location: Auditorium

17.45 - 18.45  Redefining the management of advanced prostate cancer to optimize survival
Chair: C.N. Sternberg, Rome (IT)

17.45 - 17.50  Welcome and introduction
C.N. Sternberg, Rome (IT)

17.50 - 18.05  Are we targeting prostate cancer heterogeneity in the right way?
C.N. Sternberg, Rome (IT)

18.05 - 18.20  Optimizing survival in advanced hormone-sensitive prostate cancer
G. Kramer, Vienna (AT)

18.20 - 18.35  New horizons in metastatic castration-resistant prostate cancer
M. De Santis, Coventry (GB)

18.35 - 18.45  Discussion and closing remarks
Chairman – faculty – audience
Saturday, 26 November

Location: Auditorium

13.15 - 14.15  **Personalizing treatment for patients with metastatic castration-resistant prostate cancer**
Scientific Committee/Chairs:
H. Payne, London (GB), G. Kramer, Vienna (AT)
Faculty: A. Alcaraz, Barcelona (ES)

13.15 - 13.25  **Welcome and introduction**
H. Payne, London (GB)

13.25 - 13.50  **How do comorbidities influence our choice of treatment for our patients?**
All faculty

13.50 - 14.10  **How do potential side effects influence our choice of treatment for our patients?**
All faculty

14.10 - 14.15  **Summary and close**
H. Payne, London (GB)
Exhibition: Company Profiles

ASTELLAS PHARMA EUROPE LTD.
2000 Hillswood Drive, Chertsey, Surrey, KT16 0RS, United Kingdom
T: +44 203 379 8700
W: www.astellas.eu

In 2006, Astellas made an enduring commitment to fight cancer. Since then, we have built a robust oncology R&D network and established collaborations with key organisations at the forefront of cancer research. Our goal is simple: become a worldwide leader in oncology. Our ambition is bold: significantly advance treatment of the disease. Through intense focus on the most promising new candidates and technologies, Astellas is developing a blossoming cancer drugs portfolio and a unique pipeline.

EUROPEAN ASSOCIATION OF UROLOGY (EAU)
Mr. E.N. van Kleffensstraat 5, 6842 CV Arnhem, The Netherlands
T: +31 263 89 06 80
F: +31 263 89 06 74
W: www.uroweb.org
E: info@uroweb.org

The European Association of Urology is a non-profit organisation which supports medical professionals working in the field of urology through many of its scientific, professional, educational and awareness-building initiatives. The overarching mission is to raise the level of urological care in Europe, and for many years this has been done through educational and scientific programmes aimed at urologists. Today the EAU represents more than 15,000 medical professionals working in Europe and beyond its borders. To learn more about the EAU and its membership, visit www.uroweb.org.

EUROPA UOMO
Lange Gasthuisstraat 35–37, 2000 Antwerpen, Belgium
T: +32 33 389 151
F: +32 33 389 152
W: www.europa-uomo.org
E: europauomo@skynet.be
Facebook: www.facebook.com/EuropaUomo

Europa Uomo, the European Prostate Cancer Coalition chaired by Ken Mastris (UK), represents 24 European countries and supports patient groups with prostate diseases in general and cancer in particular. Our aims include increasing awareness of prostate diseases, the support of individualized treatment based on optimal medical treatment with personalized patient care and patients’ advocacy as a priority focused on quality of life based on solidarity and mutual respect. Our expansion is based on collaboration with the professional organizations to provide information on evidence based treatment, to educate men on holistic patient care and on solidarity in advocacy with other patient support groups. Bullet points:
• A future where no man suffers with or dies from prostate cancer
• To work for all prostate cancer patients in Europe, under one umbrella, for better treatment, care and quality of life
• To support national organisations to deliver services effectively, efficiently and in line with national priorities
Exhibition: Company Profiles

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO)
Via Luigi Taddei, 4, 6962 Viganello, Switzerland
T: +41 (0)91 973 19 00
F: +41 (0)91 973 19 02
W: www.esmo.org

ESMO is the leading professional organisation for medical oncology. With more than 14,000 members representing oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. ESMO’s educational resources support an integrated, multi-professional approach to cancer care. We have European roots and global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide.

EUROPEAN SCHOOL OF ONCOLOGY (ESO)
Via Turati 29, 20121 Milan, Italy
T: +39 02 8546451
F: +39 02 85464545
W: www.eso.net
E: eso@eso.net

The European School of Oncology (ESO) was founded in 1982, with the aim of contributing to the reduction of deaths from cancer due to late diagnosis and/or inadequate treatment. Leading oncologists from around the world played a key role in founding of the School. Now, after more than 30 years, ESO is the oldest and most structured organisation exclusively dedicated to increasing the knowledge of health professionals in all fields of cancer medicine, under the auspices of an international scientific committee and advisory board.

EUROPEAN SOCIETY FOR RADIOTHERAPY & ONCOLOGY (ESTRO)
Rue Martin V 40, 1200 Brussels, Belgium
T: +32 2775 93 40
F: +32 2779 54 94
W: www.estro.org
E: info@estro.org

The European SocieTy for Radiotherapy and Oncology, ESTRO, is a non-profit and scientific organisation that advances all aspects of radiation oncology in order to improve patients’ care in the multimodality treatment of cancer. With 6,500 members in and outside Europe, ESTRO supports all the radiation oncology professionals in their daily practice: radiation oncologists, medical physicists, radiobiologists, RTTs (Radiation Therapists) and the wider oncology community. In order to achieve this, the SocieTy promotes innovation, research and dissemination of science through its congresses, special meetings, educational courses and publications.

EXACT IMAGING
7676 Woodbine Avenue, Unit 15.
Markham, ON Canada. L3R 2N2
T: +1.905.415.0030
E: info@exactimaging.com
W: www.exactimaging.com

Exact Imaging (www.exactimaging.com) introduces the world’s first high-resolution micro-ultrasound system for urological
applications. Operating up to 29 MHz, this platform enables a whole new level of resolution. The urologist, while performing the standard TRUS protocol, will now be able to visualize suspicious areas in the prostate and specifically target biopsies at those areas. Due to its unmatched resolution, this new system can now clearly visualize ducts and glands and the prostate's peripheral zone and is optimized for real-time targeting of biopsies.

EXINI DIAGNOSTICS AB
Ideon Science Park, Scheelevägen 27, SE-223 70, Lund, Sweden
T: +46 286 54 26
F: +46 286 54 29
W: www.exini.com
E: info@exini.com

EXINI develops and provides advanced software for automated image analysis, increasing accuracy and improving clinical efficiency when treating prostate cancer and other diseases. EXINI's image analysis technology combines the power of artificial neural networks, expert medical knowledge and large databases. The company's products are designed to support the visualization and quantification of disease states in automated reports. EXINI's principal product is a bone scan index product, EXINI boneBSI.

IPSEN
65 Quai Georges Gorse, 92100 Boulogne-Billancourt, Paris, France
W: www.ipsen.com

Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology. Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). For more information on Ipsen, visit www.ipsen.com.

INVIVO
3545 SW 47th Avenue, Gainesville, FL 32608 USA
T: +4007867908926
E: alex.kypriotis@philips.com
W: www.invivocorp.com

Invivo is a business of Royal Philips and has nearly over a 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices. Invivo is committed to providing technology solutions to keep pace with the needs of a growing healthcare market. Focusing on a better way for you and your patients, Invivo
Exhibition: Company Profiles

offers solutions that enable you to be more confident in your clinical practice. To learn more about Invivo solutions, visit www.invivocorp.com/

JANSSEN PHARMACEUTICA NV
Turnhoutweg 30, 2340 Beerse - Belgium
T:  +32 (0)14 60 21 11
W:  www.janssen-emea.com

The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease, and cardiovascular and metabolic diseases. Driven by our commitment to patients, Janssen develops innovative products, services and healthcare solutions to help people throughout the world. More information can be found at www.janssen-emea.com.

ONCODNA
Avenue Georges Lemaitre 25, 6041 Gosselies
T:  0032(0)71347899
W:  www.oncodna.com
E:  infos@oncodna.com

OncoDNA, The Cancer Theranostic Company, is the European leading oncology company providing solutions for cancer treatments, at the same time contributing to the knowledge applied to the fight against cancer. OncoDNA’s team is fully dedicated to help oncologists worldwide developing services to enable better treatment choices and treatment efficacy monitoring. The reports and the results from both services are displayed in a dynamic way through the web platform OncoSHARE in order to allow an easy and fast reading.

SANOFI
54, rue La Boétie, 75008 Paris, France
T:  +33 (0)1 53 77 40 00
W:  www.sanofi.com

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

SYNERGO BY MEDICAL - ENTERPRISES
Amsterdamseweg 147A, 1182GT Amstelveen, The Netherlands
T: +31 623518192
E:  synergo-med@planet.nl
W:  www.medical-enterprises.com

Medical Enterprises Group develops innovative minimally invasive technologies providing benefits for both patients and healthcare systems. The lead product, Synergo® RITE (Radiofrequency Induced Thermo-chemotherapeutic Effect) offers the clinically effective, safe and easy way to deliver the tri-modality of RF radiation (local, non-ionising), chemotherapy (cooled, recirculated) and deep tissue
hyperthermia (targeted at the tissue by the RF). Thousands of patients in 10 countries have already been successfully treated and over 40 scientific publications, including RCTs, have been published, proving its safety and efficacy and even its RFS-superiority to BCG, the gold standard of 40 years. Synergo® has become a common practice worldwide to treat intermediate and high-risk patients who, in many cases, failed previous treatments or have no other available alternatives. Synergo® treatment reduces recurrences and the need for repetitive surgical interventions and reducing the necessity for cystectomy, radiotherapy and/or expensive systemic treatments.

YURIA-PHARM LLC
Amosova str. 10, Kyiv 03680, Ukraine
T: +380 44 246 83 83
W: www.uf.ua
E: info@uf.ua

Founded in 1998, «YURiA-PHARM» focused its efforts on production of infusions and as of today is a leading infusion manufacturer not only in Ukraine, but also in CIS. We supply medical facilities with more than 100 items. of blood- and plasma substitute solutions, original infusion drugs, antibiotics, fungicidal drugs, syrups, antiseptics, parenteral nourishment preparations, anti-tuberculosis drugs, syringes, I.V. sets., unique products for osteoarthrosis treatment. Our product line sums up to more than 40 infusions, completely covering the needs of medical facilities in infusion therapy. Annual turnover of the company exceeds 60 mln bottles.
SponsorAcknowledgement

The organisers respectfully acknowledge the following sponsors for providing unrestricted educational grants and services to the:

- 8th European Multidisciplinary Meeting on Urological Cancers (EMUC);
- ESU courses on Challenging the last changes in the management of advanced and metastatic prostate cancer: Multidisciplinary approach and Multidisciplinary approach to the management of genito-urinary cancers: A clinical scenario based interactive session with the experts
- 5th Meeting of the EAU Section of Urological Imaging (ESUI);
- EMUC Symposium on GenitOURinary Pathology and Molecular Diagnostics (ESUP).
- Young Academic Urologists meeting (YAU).

Silver Sponsors

![Astellas](image1.png)  ![Sanofi Genzyme](image2.png)

Other Sponsors and Exhibitors

- BK ULTRASOUND
- EUROPA UOMO
- ESO
- EXACT IMAGING
- EXINI
- IPSEN
- INVIVO
- JANSSEN PHARMACEUTICA NV
- ONCODNA
- SYNERGO
- YURIA-PHARM
ESUI17
6th Meeting of the EAU Section of Urological Imaging
16 November 2017, Barcelona, Spain

In conjunction with the 9th European Multidisciplinary Meeting on Urological Cancers © EMUC17

An application has been made to the EACCME® for CME accreditation of this event

New technologies and limited resources
9th European Multidisciplinary Meeting on Urological Cancers

In conjunction with the
• European School of Urology (ESU)
• 6th Meeting of the EAU Section on Urological Imaging (ESUI)
• European School of Oncology: Personalised approach to prostate cancer management

Join us next year in Barcelona!

Abstract submission deadline
1 July 2017

16-19 November 2017, Barcelona, Spain

www.emuc17.org